AMTI Stock Overview
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Applied Molecular Transport Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.26 |
| 52 Week High | US$0.84 |
| 52 Week Low | US$0.13 |
| Beta | 2.29 |
| 11 Month Change | 46.68% |
| 3 Month Change | 67.52% |
| 1 Year Change | -26.21% |
| 33 Year Change | -99.15% |
| 5 Year Change | n/a |
| Change since IPO | -98.54% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Mar 07
We're A Little Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Nov 13Applied Molecular Transport GAAP EPS of -$0.93
Aug 04Companies Like Applied Molecular Transport (NASDAQ:AMTI) Could Be Quite Risky
Jul 27Applied Molecular Transport up 4% after hours on ulcerative colitis candidate data
Jul 05Applied Molecular: Interesting Drug Delivery Approach For The GI Tract
May 03We're Keeping An Eye On Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Rate
Apr 28We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Jan 08We're Hopeful That Applied Molecular Transport (NASDAQ:AMTI) Will Use Its Cash Wisely
Aug 29Applied Molecular Transport (NASDAQ:AMTI) Is In A Good Position To Deliver On Growth Plans
Apr 05Have Insiders Been Buying Applied Molecular Transport Inc. (NASDAQ:AMTI) Shares This Year?
Feb 11Here's Why We're Not Too Worried About Applied Molecular Transport's (NASDAQ:AMTI) Cash Burn Situation
Dec 21Applied Molecular Transport reports Q3 results
Nov 12Shareholder Returns
| AMTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.0% | 4.0% | 2.2% |
| 1Y | -26.2% | 18.3% | 32.6% |
Return vs Industry: AMTI underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: AMTI underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| AMTI volatility | |
|---|---|
| AMTI Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMTI's share price has been volatile over the past 3 months.
Volatility Over Time: AMTI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 13 | Shawn Cross | www.appliedmt.com |
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company’s lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects.
Applied Molecular Transport Inc. Fundamentals Summary
| AMTI fundamental statistics | |
|---|---|
| Market cap | US$10.87m |
| Earnings (TTM) | -US$74.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs AMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$42.08m |
| Gross Profit | -US$42.07m |
| Other Expenses | US$32.71m |
| Earnings | -US$74.79m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AMTI perform over the long term?
See historical performance and comparison